200 related articles for article (PubMed ID: 15877228)
1. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression.
Sinha P; Clements VK; Miller S; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2005 Nov; 54(11):1137-42. PubMed ID: 15877228
[TBL] [Abstract][Full Text] [Related]
2. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease.
Sinha P; Clements VK; Ostrand-Rosenberg S
J Immunol; 2005 Jan; 174(2):636-45. PubMed ID: 15634881
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis.
Sinha P; Clements VK; Ostrand-Rosenberg S
Cancer Res; 2005 Dec; 65(24):11743-51. PubMed ID: 16357187
[TBL] [Abstract][Full Text] [Related]
4. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent.
Ostrand-Rosenberg S; Clements VK; Terabe M; Park JM; Berzofsky JA; Dissanayake SK
J Immunol; 2002 Nov; 169(10):5796-804. PubMed ID: 12421960
[TBL] [Abstract][Full Text] [Related]
5. Signal transducer and activator of transcription 6 (Stat6) and CD1: inhibitors of immunosurveillance against primary tumors and metastatic disease.
Ostrand-Rosenberg S; Sinha P; Clements V; Dissanayake SI; Miller S; Davis C; Danna E
Cancer Immunol Immunother; 2004 Feb; 53(2):86-91. PubMed ID: 14593499
[TBL] [Abstract][Full Text] [Related]
6. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response.
Sinha P; Clements VK; Bunt SK; Albelda SM; Ostrand-Rosenberg S
J Immunol; 2007 Jul; 179(2):977-83. PubMed ID: 17617589
[TBL] [Abstract][Full Text] [Related]
7. Tumor-induced myeloid-derived suppressor cell function is independent of IFN-γ and IL-4Rα.
Sinha P; Parker KH; Horn L; Ostrand-Rosenberg S
Eur J Immunol; 2012 Aug; 42(8):2052-9. PubMed ID: 22673957
[TBL] [Abstract][Full Text] [Related]
8. Stat6 signaling promotes protective immunity against Trichinella spiralis through a mast cell- and T cell-dependent mechanism.
Urban JF; Schopf L; Morris SC; Orekhova T; Madden KB; Betts CJ; Gamble HR; Byrd C; Donaldson D; Else K; Finkelman FD
J Immunol; 2000 Feb; 164(4):2046-52. PubMed ID: 10657657
[TBL] [Abstract][Full Text] [Related]
9. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma.
Ostrand-Rosenberg S; Grusby MJ; Clements VK
J Immunol; 2000 Dec; 165(11):6015-9. PubMed ID: 11086031
[TBL] [Abstract][Full Text] [Related]
10. IL-4-induced activation of the Stat6 pathway contributes to the suppression of cell-mediated immunity and death in sepsis.
Song GY; Chung CS; Chaudry IH; Ayala A
Surgery; 2000 Aug; 128(2):133-8. PubMed ID: 10922982
[TBL] [Abstract][Full Text] [Related]
11. Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice.
Takeda K; Kamanaka M; Tanaka T; Kishimoto T; Akira S
J Immunol; 1996 Oct; 157(8):3220-2. PubMed ID: 8871614
[TBL] [Abstract][Full Text] [Related]
12. Stat 6-dependent induction of myeloid derived suppressor cells after physical injury regulates nitric oxide response to endotoxin.
Munera V; Popovic PJ; Bryk J; Pribis J; Caba D; Matta BM; Zenati M; Ochoa JB
Ann Surg; 2010 Jan; 251(1):120-6. PubMed ID: 20032720
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide contributes to host resistance against experimental Taenia crassiceps cysticercosis.
Alonso-Trujillo J; Rivera-Montoya I; Rodríguez-Sosa M; Terrazas LI
Parasitol Res; 2007 May; 100(6):1341-50. PubMed ID: 17206501
[TBL] [Abstract][Full Text] [Related]
14. Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance.
Zhou P; Szot GL; Guo Z; Kim O; He G; Wang J; Grusby MJ; Newell KA; Thistlethwaite JR; Bluestone JA; Alegre ML
J Immunol; 2000 Nov; 165(10):5580-7. PubMed ID: 11067913
[TBL] [Abstract][Full Text] [Related]
15. Crucial role of IL-4/STAT6 in T cell-mediated hepatitis: up-regulating eotaxins and IL-5 and recruiting leukocytes.
Jaruga B; Hong F; Sun R; Radaeva S; Gao B
J Immunol; 2003 Sep; 171(6):3233-44. PubMed ID: 12960353
[TBL] [Abstract][Full Text] [Related]
16. Single cell analysis reveals that IL-4 receptor/Stat6 signaling is not required for the in vivo or in vitro development of CD4+ lymphocytes with a Th2 cytokine profile.
Jankovic D; Kullberg MC; Noben-Trauth N; Caspar P; Paul WE; Sher A
J Immunol; 2000 Mar; 164(6):3047-55. PubMed ID: 10706693
[TBL] [Abstract][Full Text] [Related]
17. LncGBP9/miR-34a axis drives macrophages toward a phenotype conducive for spinal cord injury repair via STAT1/STAT6 and SOCS3.
Zhou J; Li Z; Wu T; Zhao Q; Zhao Q; Cao Y
J Neuroinflammation; 2020 Apr; 17(1):134. PubMed ID: 32345320
[TBL] [Abstract][Full Text] [Related]
18. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells.
Gallina G; Dolcetti L; Serafini P; De Santo C; Marigo I; Colombo MP; Basso G; Brombacher F; Borrello I; Zanovello P; Bicciato S; Bronte V
J Clin Invest; 2006 Oct; 116(10):2777-90. PubMed ID: 17016559
[TBL] [Abstract][Full Text] [Related]
19. Enhanced resistance in STAT6-deficient mice to infection with ectromelia virus.
Mahalingam S; Karupiah G; Takeda K; Akira S; Matthaei KI; Foster PS
Proc Natl Acad Sci U S A; 2001 Jun; 98(12):6812-7. PubMed ID: 11371617
[TBL] [Abstract][Full Text] [Related]
20. Regression of a mammary adenocarcinoma in STAT6-/- mice is dependent on the presence of STAT6-reactive T cells.
Jensen SM; Meijer SL; Kurt RA; Urba WJ; Hu HM; Fox BA
J Immunol; 2003 Feb; 170(4):2014-21. PubMed ID: 12574371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
